Migraine: anti-CGRP monoclonal antibody may progress to phase 3 trials

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Galcanezumab has a favorable safety and tolerability profile in patients with episodic migraine.

Why this matters